No. Because there are infinite hypotheses for drug improvement, disease management, and cure. And for the company to pursue that research, they need to capita

No. Because there are infinite hypotheses for drug improvement, disease management, and cure. And for the company to pursue that research, they need to capitalize on current successes. The company needs to be able to survive in downturns. Just like any company.